Top

International Journal of Clinical Oncology

Published in:

01-02-2017 | Original Article

Continuing dilemmas in the management of lymphoma during pregnancy: review of a 10-point case-based questionnaire

Authors: Amit Odelia, Joffe Erel, Perry Chava, Herishanu Yair, Sarid Nadav, Lishner Michael, Avivi Irit

Published in: International Journal of Clinical Oncology | Issue 1/2017

Abstract

Introduction

Due to the rarity of lymphoma during pregnancy, management guidelines are based upon evidence from retrospective studies and case reports. Here, we review the major dilemmas in the field and examine the approach of hemato-oncologists in Israel to the management of lymphoma in pregnancy.

Methodology

We performed a literature search on the PubMed database using keywords for all papers on the subject from 1990−2014. The papers were reviewed by an expert panel who devised a questionnaire covering the main dilemmas. Sixty questionnaires were sent out.

Results

Non-contrast magnetic resonance imaging was the staging modality of choice. Chemoimmunotherapy was considered relatively safe beyond the first trimester except methotrexate (completed postpartum). Steroids or vinblastine were suggested by most as a reasonable ‘bridging therapy’ until the second trimester in Hodgkin lymphoma. The dosage of chemoimmunotherapy employed during pregnancy remained debatable; the majority recommended dosage according to actual pregnancy weight. Optimal timing for delivery was considered by most to be >35 weeks. Regarding approach to next pregnancy for patients in complete remission from diffuse large B-cell lymphoma, 69 % advised waiting 2 years but the majority advised 6−12 months for follicular lymphoma.

Discussion

Despite consensus regarding the safety of chemotherapy post first trimester, optimal dosage, central nervous system therapy, timing of delivery and approach to future pregnancies remain controversial, indicating a need for further collaborative research in this field.

Pavlidis NA (2002) Coexistence of pregnancy and malignancy. Oncologist 7(4):279–287PubMed

Brenner B, Avivi I, Lishner M (2012) Haematological cancers in pregnancy. Lancet 379(9815):580–587. doi:10.1016/S0140-6736(11)61348-2 CrossRefPubMed

Han SN, Kesic VI, Van Calsteren K et al (2013) Cancer in pregnancy: a survey of current clinical practice. Eur J Obstet Gynecol Reprod Biol 167(1):18–23. doi:10.1016/j.ejogrb.2012.10.026 CrossRefPubMed

Lishner M, Avivi I, Apperley JF et al (2016) Hematologic malignancies in pregnancy: management guidelines from an international consensus meeting. J Clin Oncol 34(5):501–508. doi:10.1200/JCO.2015.62.4445 CrossRefPubMed

Avivi I, Farbstein D, Brenner B et al (2014) Non-Hodgkin lymphomas in pregnancy: tackling therapeutic quandaries. Blood Rev 28(5):213–220. doi:10.1016/j.blre.2014.06.004 CrossRefPubMed

NCCNclinical practice guidelines in oncology (2013) Non-Hodgkin’s Lymphomas. Version 1. http://www.nccn.org/professionals/physician_gls/pdf/nhl.pdf. Accessed 13 Novemb 2014

Kal HB, Struikmans H (2005) Radiotherapy during pregnancy: fact and fiction. Lancet Oncol 6(5):328–333. doi:10.1016/S1470-2045(05)70169-8 CrossRefPubMed

Brent RL (1989) The effect of embryonic and fetal exposure to X-ray, microwaves, and ultrasound: counseling the pregnant and nonpregnant patient about these risks. Semin Oncol 16(5):347–368PubMed

Austin LM, Frush DP (2011) Compendium of national guidelines for imaging the pregnant patient. Am J Roentgenol 197(4):W737–W746. doi:10.2214/AJR.10.6351 CrossRef

10.

Bulas D, Egloff A (2013) Benefits and risks of MRI in pregnancy. Semin Perinatol 37(5):301–304. doi:10.1053/j.semperi.2013.06.005 CrossRefPubMed

11.

Mühler MR, Clément O, Salomon LJ et al (2011) Maternofetal pharmacokinetics of a gadolinium chelate contrast agent in mice. Radiology 258(2):455–460. doi:10.1148/radiol.10100652 CrossRefPubMed

12.

Azim HA, Pavlidis N, Peccatori FA (2010) Treatment of the pregnant mother with cancer: a systematic review on the use of cytotoxic, endocrine, targeted agents and immunotherapy during pregnancy. Part II: hematological tumors. Cancer Treat Rev 36(2):110–121. doi:10.1016/j.ctrv.2009.11.004 CrossRefPubMed

13.

Evens AM, Advani R, Press OW et al (2013) Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis. J Clin Oncol 31(32):4132–4139. doi:10.1200/JCO.2013.49.8220 CrossRefPubMed

14.

Bachanova V, Connors JM (2008) How is Hodgkin lymphoma in pregnancy best treated? ASH evidence-based review. Hematol Am Soc Hematol Educ Progr 2008:33–34. doi:10.1182/asheducation-2008.1.33

15.

Connors JM (2005) State-of-the-art therapeutics: Hodgkin’s lymphoma. J Clin Oncol 23(26):6400–6408. doi:10.1200/JCO.2005.05.016 CrossRefPubMed

16.

Cardonick E, Iacobucci A (2004) Use of chemotherapy during human pregnancy. Lancet Oncol 5(5):283–291. doi:10.1016/S1470-2045(04)01466-4 CrossRefPubMed

17.

Avilés A, Neri N (2001) Hematological malignancies and pregnancy: a final report of 84 children who received chemotherapy in utero. Clin Lymphoma 2(3):173–177CrossRefPubMed

18.

Hahn KME, Johnson PH, Gordon N et al (2006) Treatment of pregnant breast cancer patients and outcomes of children exposed to chemotherapy in utero. Cancer 107(6):1219–1226. doi:10.1002/cncr.22081 CrossRefPubMed

19.

Van Calsteren K, Amant F (2010) Chemotherapy during pregnancy: pharmacokinetics and -impact on foetal neurological development. Facts Views Vis ObGyn 2(4):278–286PubMedPubMedCentral

20.

Van Calsteren K, Verbesselt R, Beijnen J et al (2010) Transplacental transfer of anthracyclines, vinblastine, and 4-hydroxy-cyclophosphamide in a baboon model. Gynecol Oncol 119(3):594–600. doi:10.1016/j.ygyno.2010.08.019 CrossRefPubMed

21.

Van Calsteren K, Verbesselt R, Ottevanger N et al (2010) Pharmacokinetics of chemotherapeutic agents in pregnancy: a preclinical and clinical study. Acta Obstet Gynecol Scand 89(10):1338–1345. doi:10.3109/00016349.2010.512070 CrossRefPubMed

22.

van Hasselt JGC, van Calsteren K, Heyns L et al (2014) Optimizing anticancer drug treatment in pregnant cancer patients: pharmacokinetic analysis of gestation-induced changes for doxorubicin, epirubicin, docetaxel and paclitaxel. Ann Oncol 25(10):2059–2065. doi:10.1093/annonc/mdu140 CrossRefPubMed

23.

Abadi U, Koren G, Lishner M (2011) Leukemia and lymphoma in pregnancy. Hematol Oncol Clin N Am 25(2):277–291. doi:10.1016/j.hoc.2011.01.001 CrossRef

24.

Brewer M, Kueck A, Runowicz CD (2011) Chemotherapy in pregnancy. Clin Obstet Gynecol 54(4):602–618. doi:10.1097/GRF.0b013e318236e9f9 CrossRefPubMed

25.

Koren G, Carey N, Gagnon R et al (2013) Cancer chemotherapy and pregnancy. J Obstet Gynaecol Cancer 35(3):263–280CrossRef

26.

Pentheroudakis G, Pavlidis N (2006) Cancer and pregnancy: poena magna, not anymore. Eur J Cancer 42(2):126–140. doi:10.1016/j.ejca.2005.10.014 CrossRefPubMed

27.

Koren G LMSS editors (2005) The Motherisk guide to cancer in pregnancy and lactation. 2nd ed, Motherisk Program, Toronto

28.

Weisz B, Meirow D, Schiff E et al (2004) Impact and treatment of cancer during pregnancy. Expert Rev Anticancer Ther 4(5):889–902. doi:10.1586/14737140.4.5.889 CrossRefPubMed

29.

Rosenzweig AI, Crews QE, Hopwood HG (1964) Vinblastine sulfate in Hodgkin’s disease in pregnancy. Ann Intern Med 61:108–112CrossRefPubMed

30.

Lishner M, Zemlickis D, Degendorfer P et al (1992) Maternal and foetal outcome following Hodgkin’s disease in pregnancy. Br J Cancer 65(1):114–117CrossRefPubMedPubMedCentral

31.

El-Hemaidi I, Robinson SE (2012) Management of haematological malignancy in pregnancy. Best Pract Res Clin Obstet Gynaecol 26(1):149–160. doi:10.1016/j.bpobgyn.2011.10.007 CrossRefPubMed

32.

Chakravarty EF, Murray ER, Kelman A et al (2011) Pregnancy outcomes after maternal exposure to rituximab. Blood 117(5):1499–1506. doi:10.1182/blood-2010-07-295444 CrossRefPubMed

33.

Decker M, Rothermundt C, Holländer G et al (2006) Rituximab plus CHOP for treatment of diffuse large B-cell lymphoma during second trimester of pregnancy. Lancet Oncol 7(8):693–694. doi:10.1016/S1470-2045(06)70797-5 CrossRefPubMed

34.

Cardonick E, Usmani A, Ghaffar S (2010) Perinatal outcomes of a pregnancy complicated by cancer, including neonatal follow-up after in utero exposure to chemotherapy: results of an international registry. Am J Clin Oncol 33(3):221–228. doi:10.1097/COC.0b013e3181a44ca9 PubMed

35.

Avilés A, Díaz-Maqueo JC, Talavera A et al (1991) Growth and development of children of mothers treated with chemotherapy during pregnancy: current status of 43 children. Am J Hematol 36(4):243–248CrossRefPubMed

36.

Pereg D, Koren G, Lishner M (2008) Cancer in pregnancy: gaps, challenges and solutions. Cancer Treat Rev 34(4):302–312. doi:10.1016/j.ctrv.2008.01.002 CrossRefPubMed

37.

Warkany J (1978) Aminopterin and methotrexate: folic acid deficiency. Teratology 17(3):353–357. doi:10.1002/tera.1420170314 CrossRefPubMed

38.

Del Campo M, Kosaki K, Bennett FC et al (1999) Developmental delay in fetal aminopterin/methotrexate syndrome. Teratology 60(1):10–12. doi:10.1002/(SICI)1096-9926(199907)60:1<10:AID-TERA5>3.0.CO;2-H CrossRefPubMed

39.

Ring AE, Smith IE, Jones A et al (2005) Chemotherapy for breast cancer during pregnancy: an 18-year experience from five London teaching hospitals. J Clin Oncol 23(18):4192–4197. doi:10.1200/JCO.2005.03.038 CrossRefPubMed

40.

Shapira T, Pereg D, Lishner M (2008) How I treat acute and chronic leukemia in pregnancy. Blood Rev 22(5):247–259. doi:10.1016/j.blre.2008.03.006 CrossRefPubMed

41.

Milojkovic D, Apperley JF (2014) How I treat leukemia during pregnancy. Blood 123(7):974–984. doi:10.1182/blood-2013-08-283580 CrossRefPubMed

42.

Wagner LK, American College of Radiology (2008) ACR practice guideline for imaging pregnant or potentially pregnant adolescents and women with ionizing radiation. Pract Guidel Tech Stand 2008 Reston, Am Coll Radiol

43.

Mazonakis M, Varveris H, Fasoulaki M, Damilakis J (2003) Radiotherapy of Hodgkin’s disease in early pregnancy: embryo dose measurements. Radiother Oncol 66(3):333–339CrossRefPubMed

44.

Jacobs C, Donaldson SS, Rosenberg SA et al (1981) Management of the pregnant patient with Hodgkin’s disease. Ann Intern Med 95(6):669–675CrossRefPubMed

45.

Van Calsteren K, Heyns L, De Smet F et al (2010) Cancer during pregnancy: an analysis of 215 patients emphasizing the obstetrical and the neonatal outcomes. J Clin Oncol 28(4):683–689. doi:10.1200/JCO.2009.23.2801 CrossRefPubMed

46.

Bastek JA, Sammel MD, Paré E et al (2008) Adverse neonatal outcomes: examining the risks between preterm, late preterm, and term infants. Am J Obstet Gynecol 199(4):367-e1. doi:10.1016/j.ajog.2008.08.002 CrossRef

47.

Pentheroudakis G, Orecchia R, Hoekstra HJ et al (2010) Cancer, fertility and pregnancy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5):v266–v273. doi:10.1093/annonc/mdq198 CrossRefPubMed

48.

Johnson S (2007) Cognitive and behavioural outcomes following very preterm birth. Semin Fetal Neonatal Med 12(5):363–373. doi:10.1016/j.siny.2007.05.004 CrossRefPubMed

49.

Weibull CE, Eloranta S, Smedby KE et al (2016) Pregnancy and the risk of relapse in patients diagnosed with hodgkin lymphoma. J Clin Oncol 34(4):337–344. doi:10.1200/JCO.2015.63.3446 CrossRefPubMed

50.

Voulgaris E, Pentheroudakis G, Pavlidis N (2011) Cancer and pregnancy: a comprehensive review. Surg Oncol 20(4):e175–e185. doi:10.1016/j.suronc.2011.06.002 CrossRefPubMed

Title: Continuing dilemmas in the management of lymphoma during pregnancy: review of a 10-point case-based questionnaire
Authors: Amit Odelia
Joffe Erel
Perry Chava
Herishanu Yair
Sarid Nadav
Lishner Michael
Avivi Irit
Publication date: 01-02-2017
Publisher: Springer Japan
Published in: International Journal of Clinical Oncology / Issue 1/2017
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-016-1036-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Introduction

Methodology

Results

Discussion

Please log in to get access to this content

Other articles of this Issue 1/2017

Estimation of Physiologic Ability and Surgical Stress (E-PASS) versus modified E-PASS for prediction of postoperative complications in elderly patients who undergo gastrectomy for gastric cancer

Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung cancer

Clinical outcomes of IMRT planned with or without PET/CT simulation for patients with pharyngeal cancers

Sentinel lymph node biopsy using indocyanine green fluorescence in early-stage breast cancer: a meta-analysis

Psychological impact of positive cervical cancer screening results among Japanese women

One-step nucleic acid amplification (OSNA): where do we go with it?

Keynote webinar | Spotlight on antibody–drug conjugates in cancer